Press Room

AAPS 2018

Start
Sunday, November 04, 2018 - 00:00
End
Wednesday, November 07, 2018 - 00:00
Location: Washington DC, United States
Booth Number: 2309
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster name / Presentation Authors / Presenter Poster # and Presenter Presentation  Date / Time
Use of Hot Melt Extrusion for the production of controlled release diclofenac formulation with PLGA/PLA - standard and accelerated IVR methods João Henriques #M1030-07-056 - João Henriques Monday, Nov 5

10:30 – 11:30 
Microfludization for Solubility Enhancement – One Technology Fits All Fonseca, T., Duarte, I., Vicente, J.,

Temtem, M
#M1430-10-075 - Iris Duarte Monday, Nov 5

14:30 – 15:30 
Performance evaluation during process development: different techniques, complementary results Luis Sousa #M1530-07-049 - Luis Sousa Monday, Nov 5

15:30 – 16:30 
Identify your limits: definition of Spray drying Tout based on a novel methodology to measure powder stickiness  Luis Sousa #T1130-07-050 - Luis Sousa Tuesday, Nov 6

11:30 – 12:30 
Laser diffraction analysis of supersaturated solutions and application to screening of amorphous dispersions  Luis Sousa #T1230-07-049 - Luis Sousa Tuesday, Nov 6

12:30 – 13:30 
Effect of Surfactant Level on Properties of Celecoxib Amorphous Solid Dispersion  Fan Meng, Rui Ferreira,

Feng Zhang
#T1330-09-065  Tuesday, Nov 6

13:30 – 14:30 
Miniaturized methodology of polymer screening for spray dried dispersions  Luis Sousa #W0930-07-050 - Luis Sousa Wednesday, Nov 7

9:30 – 10:30 
New formulation screening approach to optimize tablet disintegration profiles based on cloud/precipitation point measurement João Henriques #W1030-13-097 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
How to develop an amorphous solid dispersion in tablets with less than 30 g API João Henriques #W1030-13-100 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
DPI Carrier-Based Formulation Scale-Up: A Statistical Analysis Approach Marcio Temtem, Filipa Maia,

Isabel Lopes, Luis Sousa,

Maria Braga, Nuno Neves
#W1230-09-068 - Eunice Costa  Wednesday, Nov 7

12:30 – 13:30 
Simulating the Pulmonary Route: From Actuation to Absoption Beatriz Fernandes, Maria Malmlof,

Marcio Temtem,

M. Luisa Corvo,

Per Gerde, Eunice Costa
#W1230-09-065  Wednesday, Nov 7

12:30 – 13:30 
Molecular Interactions between Rafoxanide and Povidone for Amorphous Solid Dispersion Preparation and Feng Zhang. Fan Meng, Zhifeng Jing,

Yongchao Su, Rui Ferreira, Pengyu Ren 
   

 

 

 

 

 

 

 

 

 

 

 

 

 

You might be also interested in

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026